What Provectus Biopharmaceuticals Inc's executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Morris Jeffrey Allen | 10% owner | Aug 12 | Derivative Conversion · C | +264,314 | $2.86 | +$756K | 4,260,061 |
| Morris Jeffrey Allen | 10% owner | May 08 | Derivative Conversion · C | +188,757 | $2.86 | +$540K | 3,995,747 |
| Lacy John Iii | Director | Nov 10 | Grant / award · A | +100,000 | — | — | 200,000 |
| Horowitz Bruce | Chief Operating Officer | Nov 10 | Grant / award · A | +800,000 | — | — | 2,227,243 |
| Raines Heather | CFO | Nov 10 | Grant / award · A | +50,000 | — | — | 1,213,153 |
| Raines Heather | Chief Financial Officer | Mar 25 | Grant / award · A | +50,000 | — | — | 1,163,153 |
| Glass John R | See Remarks | Dec 14 | Open-market buy · P | +115,900 | $0.05 | +$6.26K | 200,000 |
| Glass John R | See Remarks | Dec 14 | Open-market buy · P | +84,100 | $0.05 | +$4.53K | 84,100 |
| Koe Jan | Director | Mar 29 | Out-of-money Exercise · O | +100,000 | $1.25 | +$125K | 786,300 |
| Koe Jan | Director | Mar 29 | Out-of-money Exercise · O | +100,000 | $1.25 | +$125K | 686,300 |
| Culpepper Peter R | Interim CEO, CFO, COO | Mar 29 | Out-of-money Exercise · O | +106,000 | $1.00 | +$106K | 296,503 |
| Culpepper Peter R | Interim CEO, CFO, COO | Mar 29 | Out-of-money Exercise · O | +27,333 | $1.00 | +$27.3K | 1,411,829 |
| Culpepper Peter R | Interim CEO, CFO, COO | Mar 29 | Out-of-money Exercise · O | +133,333 | $1.00 | +$133K | 1,384,496 |
| Wachter Eric Phd | Chief Technology Officer | Mar 29 | Out-of-money Exercise · O | +106,000 | $1.00 | +$106K | 930,248 |
| Wachter Eric Phd | Chief Technology Officer | Mar 29 | Out-of-money Exercise · O | +200,947 | $1.00 | +$201K | 5,714,183 |
| Wachter Eric Phd | Chief Technology Officer | Dec 21 | Exercise / conversion · M | +120,000 | $1.02 | +$122K | 5,513,236 |
| Culpepper Peter R | CFO & COO | Dec 09 | Exercise / conversion · M | +6,383 | $0.94 | +$6K | 190,503 |
| Culpepper Peter R | CFO & COO | Dec 09 | Exercise / conversion · M | +138,831 | $0.94 | +$131K | 1,251,163 |
| Wachter Eric Phd | Chief Technology Officer | Jan 24 | Exercise / conversion · M | +185,000 | $1.02 | +$189K | 824,248 |
| Culpepper Peter R | CFO & COO | Jan 07 | Exercise / conversion · M | +29,786 | $0.94 | +$28K | 184,120 |
Loading...
